The WMA GmbH – 13th Immunotherapy of Cancer Conference (ITOC13) will take place from March 4–6, 2027, in Munich, Germany.

ITOC is a European meeting providing a global platform for translational research in immuno-oncology, with a focus on early clinical translation and the challenges involved in advancing cancer immunotherapies. itoc-conference

ITOC13 is organized by WMA GmbH in scientific cooperation with the ITOC Association, Tumor Centre in Munich (TZM), Wolfgang Wilmanns Stiftung (WWS), German Cancer Consortium (DKTK), Central European Cooperative Oncology Group (CECOG), Chinese American Hematologist and Oncologist Network (CAHON), and Comprehensive Cancer Center Munich (CCCM).

The conference aims to provide a platform for researchers and clinicians involved in cancer immunotherapy to exchange knowledge and discuss the latest findings shaping oncology drug development and delivery. itoc-conference

The preliminary scientific programme covers topics including tumor immunology and immunometabolism, new therapeutic targets, local immunotherapies, bispecific antibodies, multiple myeloma, next-generation immune-activating concepts, and emerging immunotherapy approaches, alongside presentations from submitted abstracts and a dedicated young researcher session.